Dr. Rogers on Reducing Risk of Tumor Lysis Syndrome in CLL

Video

In Partnership With:

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia (CLL).

The goal of the 2-year, phase Ib/II study was to test the 3 most effective drugs for the treatment of CLL—obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Venclexta). Rogers says these agents work because they each have complimentary mechanisms and nonoverlapping toxicity. For the purposes of the trial, the agents were started sequentially in month-long cycles, 1 per cycle.

Since data show that venetoclax has a risk of tumor lysis syndrome that increases when tumor mutational burden is high, investigators started the venetoclax cycle last to try to maximize disease reduction with the earlier agents. Rogers said investigators focused specifically on disease reduction after the first 2-month period.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD